These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28190681)

  • 1. Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
    Wang CP; Lorenzo C; Habib SL; Jo B; Espinoza SE
    J Diabetes Complications; 2017 Apr; 31(4):679-686. PubMed ID: 28190681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
    Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
    BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population.
    Itoga NK; Rothenberg KA; Suarez P; Ho TV; Mell MW; Xu B; Curtin CM; Dalman RL
    J Vasc Surg; 2019 Mar; 69(3):710-716.e3. PubMed ID: 30197158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
    Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
    Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality.
    Xu H; Aldrich MC; Chen Q; Liu H; Peterson NB; Dai Q; Levy M; Shah A; Han X; Ruan X; Jiang M; Li Y; Julien JS; Warner J; Friedman C; Roden DM; Denny JC
    J Am Med Inform Assoc; 2015 Jan; 22(1):179-91. PubMed ID: 25053577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.
    Fung CS; Wan EY; Wong CK; Jiao F; Chan AK
    Cardiovasc Diabetol; 2015 Oct; 14():137. PubMed ID: 26453464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
    Wang F; He Y; Zhang R; Zeng Q; Zhao X
    Medicine (Baltimore); 2017 Sep; 96(36):e7638. PubMed ID: 28885325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
    Campbell JM; Bellman SM; Stephenson MD; Lisy K
    Ageing Res Rev; 2017 Nov; 40():31-44. PubMed ID: 28802803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
    Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
    Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.